Haemonetics (HAE): CSL plans full US NexSys rollout by end of 2027

By Centiview Research•Published 12 Oct 2026, 04:35 UTC•1 min read

CSL now expects to move all its current US plasma centers to Haemonetics' NexSys devices by end-2027, up from "a portion" with no timeline in August. Shares jumped double digits. The deal is non-exclusive, has no minimum purchases, and guidance is unchanged for now.

Sources

For information only. Not financial advice. See our disclaimer and editorial standards. Spotted an error? Tell us.

Related takes

Viatris (VTRS): Agrees to buy Pacira BioSciences for $1.65 billion in cash

Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, adding non-opioid pain drugs Exparel and Zilretta. Pacira jumped roughly 44%…

Centiview • 13 Oct 2026Healthcare

Bristol Myers Squibb (BMY): Pulmonary fibrosis drug admilparant hits Phase 3 goal at 60 mg

Bristol Myers said admilparant met the primary goal in its Phase 3 ALOFT-IPF trial at 60 mg, but the 120 mg dose slowed lung decline without a…

Centiview • 12 Oct 2026Healthcare

Humana (HUM): Shares jump as 2027 star ratings improve sharply

Humana rose about 15% on Oct 9 after CMS's 2027 Medicare Advantage star ratings. Humana says about 95% of members are in plans rated 4 stars or…

Centiview • 12 Oct 2026Healthcare